Role of Transferrin Receptor and the ABC Transporters ABCB6 and ABCB7 for Resistance and Differentiation of Tumor Cells towards Artesunate

被引:87
作者
Kelter, Gerhard [2 ]
Steinbach, Daniel [3 ]
Konkimalla, Venkata Badireenath [1 ]
Tahara, Tsuyoshi [4 ]
Taketani, Shigeru [4 ]
Fiebig, Heinz-Herbert [2 ]
Efferth, Thomas [1 ]
机构
[1] German Canc Res Ctr, D-6900 Heidelberg, Germany
[2] Oncotest GmbH, Inst Expt Oncol, Freiburg, Germany
[3] Univ Ulm, Dept Pediat, D-7900 Ulm, Germany
[4] Kyoto Inst Technol, Dept Biotechnol, Kyoto 606, Japan
来源
PLOS ONE | 2007年 / 2卷 / 08期
关键词
D O I
10.1371/journal.pone.0000798
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The anti-malarial artesunate also exerts profound anti-cancer activity. The susceptibility of tumor cells to artesunate can be enhanced by ferrous iron. The transferrin receptor (TfR) is involved in iron uptake by internalization of transferrin and is over-expressed in rapidly growing tumors. The ATP-binding cassette (ABC) transporters ABCB6 and ABCB7 are also involved in iron homeostasis. To investigate whether these proteins play a role for sensitivity towards artesunate, Oncotest's 36 cell line panel was treated with artesunate or artesunate plus iron(II) glycine sulfate (Ferrosanol (R)). The majority of cell lines showed increased inhibition rates, for the combination of artesunate plus iron(II) glycine sulfate compared to artesunate alone. However, in 11 out of the 36 cell lines the combination treatment was not superior. Cell lines with high TfR expression significantly correlated with high degrees of modulation indicating that high TfR expressing tumor cells would be more efficiently inhibited by this combination treatment than low TfR expressing ones. Furthermore, we found a significant relationship between cellular response to artesunate and TfR expression in 55 cell lines of the National Cancer Institute (NCI), USA. A significant correlation was also found for ABCB6, but not for ABCB7 in the NCI panel. Artesunate treatment of human CCRF-CEM leukemia and MCF7 breast cancer cells induced ABCB6 expression but repressed ABCB7 expression. Finally, artesunate inhibited proliferation and differentiation of mouse erythroleukemia (MEL) cells. Down-regulation of ABCB6 by antisense oligonucleotides inhibited differentiation of MEL cells indicating that artesunate and ABCB6 may cooperate. In conclusion, our results indicate that ferrous iron improves the activity of artesunate in some but not all tumor cell lines. Several factors involved in iron homeostasis such as TfR and ABCB6 may contribute to this effect.
引用
收藏
页数:7
相关论文
共 47 条
[1]  
ALLEY MC, 1988, CANCER RES, V48, P589
[2]   Artemisinin-based combinations [J].
Ashley, EA ;
White, NJ .
CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (06) :531-536
[3]  
Berger TG, 2005, ONCOL REP, V14, P1599
[4]   Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation [J].
Boonstra, R ;
Timmer-Bosscha, H ;
van Echten-Arends, J ;
van der Kolk, DM ;
van den Berg, A ;
de Jong, B ;
Tew, KD ;
Poppema, S ;
de Vries, EGE .
BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2411-2417
[5]  
BOUSTOS MD, 1994, B WORLD HEALTH ORGAN, V72, P729
[6]   The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer [J].
Daniels, Tracy R. ;
Delgado, Tracie ;
Rodriguez, Jose A. ;
Helguera, Gustavo ;
Penichet, Manuel L. .
CLINICAL IMMUNOLOGY, 2006, 121 (02) :144-158
[7]   DEVELOPMENT OF A PROPIDIUM IODIDE FLUORESCENCE ASSAY FOR PROLIFERATION AND CYTOTOXICITY ASSAYS [J].
DENGLER, WA ;
SCHULTE, J ;
BERGER, DP ;
MERTELSMANN, R ;
FIEBIG, HH .
ANTI-CANCER DRUGS, 1995, 6 (04) :522-532
[8]   Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron [J].
Efferth, T ;
Benakis, A ;
Romero, MR ;
Tomicic, M ;
Rauh, R ;
Steinbach, D ;
Häfer, R ;
Stamminger, T ;
Oesch, F ;
Kaina, B ;
Marschall, M .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (07) :998-1009
[9]   Molecular modes of action of artesunate in tumor cell lines [J].
Efferth, T ;
Sauerbrey, A ;
Olbrich, A ;
Gebhart, E ;
Rauch, P ;
Weber, HO ;
Hengstler, JG ;
Halatsch, ME ;
Volm, M ;
Tew, KD ;
Ross, DD ;
Funk, JO .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :382-394
[10]  
Efferth T, 1996, ARZNEIMITTEL-FORSCH, V46, P196